New drug ABBV-8736 tested in healthy people for first time
NCT ID NCT07141199
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and how the body handles ABBV-8736 in 24 healthy adults. Participants received either the drug or a placebo through an IV. The goal was to check for side effects and measure drug levels in the blood, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-8736
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acpru /Id# 277377
Grayslake, Illinois, 60030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?